Cellebrite DI (NASDAQ:CLBT) Stock Price Target Cut by JPMorgan Chase & Co.

Cellebrite DI (NASDAQ:CLBT) had its price target reduced by equities researchers at JPMorgan Chase & Co. from $16.00 to $15.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 27.98% from the stock’s current price.

Several other analysts have also recently commented on CLBT. Weiss Ratings cut shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 27th. Needham & Company LLC lifted their target price on shares of Cellebrite DI from $12.50 to $14.00 and gave the company a “buy” rating in a research note on Thursday. DA Davidson restated a “buy” rating and set a $15.00 price target on shares of Cellebrite DI in a report on Tuesday, September 15th. Finally, Lake Street Capital dropped their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.75.

Cellebrite DI Trading Up 7.6%

Shares of CLBT traded up $0.83 during midday trading on Friday, hitting $11.72. The stock had a trading volume of 2,965,446 shares, compared to its average volume of 2,270,214. The business has a 50-day simple moving average of $11.61 and a two-hundred day simple moving average of $13.24. Cellebrite DI has a fifty-two week low of $9.58 and a fifty-two week high of $19.39. The firm has a market cap of $2.92 billion, a P/E ratio of 53.29, a price-to-earnings-growth ratio of 1.95 and a beta of 1.06.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, November 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.08. Cellebrite DI had a net margin of 11.43% and a return on equity of 15.58%. The firm had revenue of $149.02 million for the quarter, compared to analysts’ expectations of $145.83 million. On average, analysts expect that Cellebrite DI will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cellebrite DI news, insider Thomas E. Hogan sold 25,299 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total transaction of $285,625.71. Following the completion of the sale, the insider directly owned 765,249 shares in the company, valued at $8,639,661.21. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CRO Marcus Jewell sold 12,562 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $11.24, for a total value of $141,196.88. Following the completion of the sale, the executive directly owned 427,128 shares in the company, valued at approximately $4,800,918.72. This represents a 2.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 56,909 shares of company stock worth $641,890 over the last ninety days. Company insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Cellebrite DI

Several large investors have recently bought and sold shares of CLBT. Nine Ten Capital Management LLC increased its holdings in shares of Cellebrite DI by 19.8% during the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock worth $60,251,000 after purchasing an additional 682,933 shares during the period. Wellington Management Group LLP lifted its stake in shares of Cellebrite DI by 93.7% in the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after buying an additional 1,475,579 shares during the period. Renaissance Technologies LLC grew its position in Cellebrite DI by 14.7% during the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock worth $39,420,000 after buying an additional 365,700 shares in the last quarter. Principal Financial Group Inc. grew its position in Cellebrite DI by 33.9% during the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock worth $29,712,000 after buying an additional 545,334 shares in the last quarter. Finally, Weiss Asset Management LP grew its position in Cellebrite DI by 3,485.3% during the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after buying an additional 1,846,851 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Cellebrite DI

Investors following CLBT have been watching these headlines:

• Positive Sentiment: Needham & Company raised its price target to $14 from $12.50 and reaffirmed a “buy” rating, signaling greater confidence in the shares. Needham rating information
• Neutral Sentiment: Full-year 2026 revenue guidance of $553 million–$558 million brackets the $556.8 million consensus estimate, making the annual outlook broadly in line with expectations. Company results and guidance
• Negative Sentiment: Q4 revenue guidance of $145 million–$150 million is below the $151.6 million analyst consensus, a potential near-term headwind despite the strong quarter. Company results and guidance

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.